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Abstract
Background: Neonatal screening for Pompe disease has been introduced in Taiwan and a few U.S. states, while
other jurisdictions including some European countries are piloting or considering this screening. First-tier screening
flags both classic infantile and late-onset Pompe disease, which challenges current screening criteria. Previously,
advocacy groups have sometimes supported expanded neonatal screening more than professional experts, while
neutral citizens’ views were unknown. This study aimed to measure support for neonatal screening for Pompe
disease in the general public and to compare it to support among (parents of) patients with this condition. The
study was done in the Netherlands, where newborns are not currently screened for Pompe disease. Newborn
screening is not mandatory in the Netherlands but current uptake is almost universal.
Methods: A consumer panel (neutral group) and (parents of) patients with Pompe disease (Pompe group) were
sent information and a questionnaire. Responses were analyzed of 555 neutral and 58 Pompe-experienced
informants who had demonstrated sufficient understanding.
Results: 87% of the neutral group and 88% of the Pompe group supported the introduction of screening (95% CI
of difference -10 to 7%). The groups were similar in their moral reasoning about screening and acceptance of false
positives, but the Pompe-experienced group expected greater benefit from neonatal detection of late-onset
disease. Multivariate regression analysis controlling for demographics confirmed that approval of the introduction
of screening was independent of having (a child with) Pompe disease. Furthermore, respondents with university
education, regardless of whether they have (a child with) Pompe disease, were more likely to be reluctant about
the introduction of screening than those with less education, OR for approval 0.29 (95% CI 0.18 to 0.49, p < 0.001).
Conclusions: This survey suggests a rather high level of support for newborn screening for Pompe disease, not
only among those who have personal experience of the disease but also among the general public in the
Netherlands. Optional screening on the basis of informed parental consent is probably unrealistic, underlining the
need for new guidelines to help policymakers in their consideration of newborn screening for broad phenotype
conditions.
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Background
New treatments as well as high-throughput and multi-
plex screening methods are stimulating policymakers
and legislators to consider adding new diseases to
blood-based neonatal screening panels. An internation-
ally accepted goal of neonatal screening is benefit for
the neonate [1]. Lately, neonatal screening policy discus-
sion is also addressing the value of genetic knowledge
for family members besides the infant [2] and the value
of a predictive diagnosis without the (immediate) possi-
bility or need for intervention [3]. Several lysosomal sto-
rage disorders are being considered in the context of
expanded neonatal screening (reviewed in [4]), including
Pompe disease.
Pompe disease (MIM ID #232300) is an autosomal
recessive enzyme deficiency due to mutations in the
gene coding for acid alpha-glucosidase (GAA; MIM ID
*606800). Insufficient alpha-glucosidase activity leads to
accumulation of glycogen in the cells and eventually to
progressive muscle weakness. Pompe disease has a
broad geno- and phenotypic spectrum. The most severe,
classic infantile form of disease has a birth prevalence of
about 1:138,000 in the Netherlands [5]. It presents at a
median age of 1.6 months but is usually diagnosed
between 4.5 and 5.3 months [6]. The natural course of
classic infantile disease includes cardiac hypertrophy and
rapidly progressive muscle weakness; without treatment,
infants rarely survive beyond 1 year of age [7]. Pre- and
post-marketing studies taken together show that enzyme
replacement therapy has a positive effect on the heart,
prevention of muscle weakness and life expectancy,
especially when treatment starts early. However, some
children with classic infantile Pompe disease do not get
long-term benefit from enzyme replacement therapy,
even when it is given promptly. One predictive factor is
CRIM status (cross-reactive immunological material),
which reflects whether patients produce any endogenous
acid alpha-glucosidase [8,9].
Besides the classic infantile form of Pompe disease,
there is a milder, more slowly progressive form often
referred to as late-onset which affects about 1:57,000
people [5]. It is often referred to as late-onset Pompe
disease and this term will be used in this paper, though
it must be stressed that this slowly progressive form can
manifest at almost any age, from infancy through the
fifth decade, often with a considerable delay between
first complaints and diagnosis [10]. The heart is not
affected but there is progressive, proximal muscle weak-
ness and often respiratory problems. Many patients
become dependent on assisted ventilation and need a
wheelchair. An 18-month randomized, controlled trial
showed a modest but significant positive effect of
enzyme replacement therapy on the ability to walk and
on the stabilization of pulmonary function [11]. This
and earlier studies suggest that the better the condition
of the patient at start of therapy, the greater the benefit.
Late-onset patients currently receiving therapy may have
been diagnosed decades before therapy was available.
Therefore the full potential of therapy will not be
known until greater numbers of patients have started
treatment soon after diagnosis. A separate question is
how best to shorten the delay between first complaints
and diagnosis.
The first large-scale experience of neonatal screening
for Pompe disease, including clinical follow-up, comes
from Taiwan. Over 300,000 newborns have been
screened using a fluorimetric assay and evolving diag-
nostic algorithms which include the relative amount of
acarbose-resistant acid alpha glucosidase [12-14]. Full
performance statistics have not been published since the
pilot phase of the program when false positive rates
were rather high [12]. Clinical benefit of neonatal
screening has been reported for classic infantile cases
(all CRIM positive) [13]. The screening and diagnostic
algorithms in Taiwan have so far led to identification of
13 infants without cardiac involvement, who have been
classified with ‘later-onset’ Pompe disease. They were
put under surveillance, and some have started treatment
with enzyme replacement therapy [14]. Pilot studies
without clinical follow-up have been done using various
techniques, in Japan [15], Austria [16] the United States
[17] and northern Germany [18]. At the time of writing,
four U.S. states have mandated screening for Pompe dis-
ease to start by 2012 [4].
Currently published first-tier screening methods using
blood spots cannot distinguish between classic infantile
and late-onset Pompe disease. Confirmatory testing,
which includes clinical and laboratory procedures, will
identify classic infantile cases but will alert even more
parents to the possibility of late-onset disease in their
child. Although a severity-rating scale for GAA muta-
tions has been developed [19], genotyping offers little
certainty in predicting the age of symptom onset and
the rate of disease progression for late-onset patients
[20,21]. Thus some infants flagged by screening will
become “patients-in-waiting” [22,23]. The ethical com-
plexity of neonatal screening for Pompe disease has
indeed been recognized in the literature [24-28]. Neona-
tal screening for Pompe disease will detect more than
twice as many late-onset cases as classic infantile cases;
in fact it is likely that the proportion of late-onset cases
is currently underestimated, as neonatal screening for
other lysosomal storage disorders has identified larger
than expected numbers of (probable) late-onset cases
[29-31]. This prospect raises the question of whether
the expected benefits of neonatal screening for Pompe
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disease do indeed outweigh its possible drawbacks. This
issue of ‘proportionality’ is especially important if the
screen falls under a directive paradigm of protection
through public health. It might be less problematic
under a paradigm of individual choice by consumers.
Although previous studies have addressed parental
acceptability of neonatal screening for a treatable late-
onset disease [32,33] or a hypothetical, untreatable late-
onset disease, [34] there is a lack of studies which
address acceptability of neonatal screening for a treata-
ble disease of broad phenotype such as Pompe disease.
The aims of this study were to measure support for
neonatal screening for Pompe disease in the general
public and to test whether (parents of) patients differ
from the general public in their support for neonatal
screening for their condition. A questionnaire specific to
neonatal screening for Pompe disease was developed.
The study aimed at a broad age range of informants, in
contrast to previous studies on hypothetical acceptability
of expanded neonatal screening in the general popula-
tion which targeted prospective parents or parents with
children under 18 [34,35].
A broad age base was sought because neonatal screen-
ing for Pompe disease touches on long-term predictive
testing, an emerging field which may affect people in
many phases of life. The questionnaire was grounded in
descriptive ethics [36]. Screening can be studied as a
public health issue (should the state implement it for
the benefit of the population?) or as a matter of indivi-
dual choice (does the informed consumer want to use
the test?). In this study, informants were asked to think
along both perspectives. This approach is relevant for
jurisdictions like the Netherlands where although new-
born screening is a routine procedure with high uptake,
it is not mandatory. The main outcome measures were
(1) informed judgement on whether the government
should offer neonatal screening for Pompe disease and
(2) informed, hypothetical choice to use the screening.
The size of the respondent groups permitted exploration
of a few extra demographic variables which might
explain the main outcome measures. Educational level
was chosen because it has been shown previously that
lower educational level is associated with stronger will-
ingness to extend neonatal screening criteria [35]. Gen-
der was also included because male respondents are
underrepresented in many surveys on issues in neonatal
screening e.g. [35,37]. The survey included two other
major features. It explored the moral reasoning for the
main outcome measures, focussing on ethical principles
which often appear in discourse on neonatal screening
frameworks. Finally, the survey offset benefits and
harms of neonatal screening for Pompe disease in case
of a positive first-tier blood spot test.
Methods
Overview of study design
Using a newly developed questionnaire we surveyed
members of a consumer panel and (parents of) patients
with Pompe disease in 2010. The study was approved by
the institutional review boards of the Erasmus MC Uni-
versity Medical Center and the VU University Medical
Center.
Study population
The Dutch Health Care Consumer Panel is maintained
by the Netherlands Institute for Health Services
Research (NIVEL) [38]. The panel consists of Dutch
individuals over 18 who may be members for three
years. Members are recruited using address files pur-
chased from an address file supplier. All 1500 panel
members were invited for this study. They were offered
the standard incentive of a chance to win a 15 Euro gift
certificate.
The Dutch Association for Neuromuscular Diseases
(VSN) offers membership to patients, their family mem-
bers and other associates over 18, including survivors of
deceased patients. 100 members (associated) with
Pompe disease were eligible for this study. Multiple
associates for a single patient were allowed but survivors
of deceased patients were excluded.
Study size
Study size was based on the convenience of a 1500-
member consumer panel and on maximal ascertainment
of the Pompe (associated) population in the
Netherlands.
Questionnaire overview
Since the survey dealt with a rare disease and a health
service, neonatal screening, which gets little publicity, it
was necessary to inform participants about the state of
the art before asking their opinion. The questionnaire
therefore started with illustrated background informa-
tion on Pompe disease and neonatal screening, including
a flow chart for screening and follow-up. To ensure
validity of the survey, comprehension was tested and
used as an inclusion criterion. The questionnaire also
contained vignettes describing three outcomes of a posi-
tive neonatal screening test for Pompe disease: classic
infantile disease, a false positive result, and early detec-
tion of (probable) late-onset disease. The expected inci-
dence of false-positives was calculated by multiplying
the hypothetical recall rate from the Austrian pilot
study [16] with the number of annual births in the
Netherlands. Additional files show an English translation
of the original Dutch cover letter [Additional file 1] and
the questionnaire used to survey (parents of) patients
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[Additional file 2]. The questionnaire used for the con-
sumer panel (not shown) had a slightly different lay-out
and omitted demographic items which were already
known.
Questionnaire development and pre-test
The questionnaire was meant to be understood by peo-
ple who have completed secondary education, i.e. at
least pre-vocational secondary school. The background
description of Pompe disease was based on lay bro-
chures of the Dutch Association for Neuromuscular Dis-
eases but also included additional information. The
legibility standard recommended by the Netherlands
Central Committee on Research Involving Human Sub-
jects was followed [39].
The questionnaire was pre-tested in 2 phases, with the
aim of trouble-shooting [40]. Readers included 12 non-
specialists, a patient with late-onset Pompe disease and
a professional communication specialist. It took up to
30 minutes to complete the questionnaire.
Measures and scoring
A supplementary table summarizes the measures used in
the questionnaire [Additional file 3]. Comprehension
questions were scored as correct or other (incorrect or
‘don’t know’). A threshold for sufficient comprehension
was set at ≥ 3 out of 4 correct answers, including a cor-
rect answer to the question on the discriminatory power
of the heel stick screening. (Additional file 3, item 4)
Scaled items were scored 1 to 3 or 1 to 5
Educational level was grouped into 3 categories: low
(through primary or prevocational secondary school),
middle (secondary or vocational school), and high (tech-
nical or academic university).
The 2 consumer panel members who reported Pompe
disease (in the family) were analyzed together with all
the patient organisation members.
The decisive reason (not) to use screening (items 20, 22)
was considered valid only if the respondent had correctly
followed the flow from item 18 [see Additional file 3].
Ethnicity was coded as Dutch, other Western or non-
Western by the following algorithm: by country of birth
if not the Netherlands, if the Netherlands then by coun-
try of birth of mother, if the subject and mother were
both born in the Netherlands then by country of father
[41].
Acceptability of the questionnaire was categorized for
non-responders who supplied a reason for nonresponse
as “advanced age or no children”, “too difficult” or
“other”.
Data collection and handling
Questionnaires were sent to members of the consumer
panel and patient organisation in February 2010. Three
weeks later a reminder was sent to non-responders.
Questionnaires were processed if they were returned
within 3 weeks by the consumer panel or within about
6 weeks by patient organisation members.
Data of the consumer panel was entered manually at
NIVEL and linked with previously collected demo-
graphic data including non-responder panel members.
These anonymous databases were then transferred to
the VU University Medical Center. The two consumer
panel members who reported having Pompe disease (in
the family) were not contacted for verification.
Anonymous data of members of the Dutch Associa-
tion for Neuromuscular Diseases was entered manually
in SPSS at the VU University Medical Center. Logical
checks were performed and a 10% sample of the entered
data was checked by an independent reader, who found
no errors in data entry.
Efforts to address bias
The composition of the consumer panel is meant to
reflect the demographics of the Dutch population, [38]
but responders to the questionnaire and the subgroup
which demonstrated sufficient comprehension cannot be
assumed to be a random sample. Therefore, for analyses
where panel opinion was extrapolated to the Dutch
population, direct standardization was performed for age
and gender, or for educational level. Weights for educa-
tional level were calculated with data from Statistics
Netherlands [42]. Weights for age and gender were sup-
plied by NIVEL, based on 2009 data from Statistics
Netherlands. Non-response was analyzed by educational
level and from self-reported reasons for non-response.
Measures not analysed
Questions on the most important advantage and disad-
vantage of screening for classic infantile Pompe (items 5
and 6) were put in the questionnaire to provoke thought
but were not intended for analysis, because this scenario
does not challenge ethical principles of current screen-
ing criteria. (These items were in fact used in a post-hoc
subgroup analysis, see Qualitative analysis.) It was not
possible to meaningfully test the relationship between
age and attitude to screening, due to low representation
of certain age categories, notably the age category corre-
sponding to young parenthood. Non-Dutch ethnicity
was strongly underrepresented in the study population
(see [43]); therefore the relationship between ethnicity
and attitude to screening was not analyzed. In practice,
people with Pompe disease (in the family) would have
access to clinical genetic services before a new preg-
nancy and therefore it is of limited relevance to explore
their hypothetical use of screening. For this reason
Pompe status was not included in regression analysis of
use of screening nor was the decisive moral reason for
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(not) using screening analyzed for this group; however, a
raw figure for hypothetical use of screening is reported.
Qualitative analysis
In a post-hoc subgroup analysis of opponents to a gov-
ernment offer of screening, free-text responses on the
most important advantage and disadvantage of screening
in the scenario of classic infantile Pompe disease (items
5 and 6) were analyzed to see if informants had men-
tioned any merits for screening in the classic infantile
scenario. Open coding was done, by one author (SSW)
[44].
Statistical methods
Statistical analysis was done with SPSS for Windows
(version 15.0.1, SPSS Inc., Chicago, IL.)
Differences in proportion were tested with Pearson’s
chi square or Fisher’s exact test if any cells had an
expected count < 5. Continuous variables were not nor-
mally distributed and groups were compared with the
Mann Whitney Wilcoxon U-test. Ordinal variables from
scaled items are reported as means. For ordinal, includ-
ing scaled, items differences between groups were tested
with the chi squared test for trend; exact 2-sided signifi-
cance is reported if any cells had an expected count < 5.
95% confidence intervals for single proportions and
for differences of proportions were calculated with the
software program CIA (Confidence Interval Analysis)
with the accurate Wilson-type methods described by
Newcombe and Altman [45]. 95% confidence intervals
for directly standardized proportions were calculated
with CIA by the method described by Morris and Gard-
ner [46].
In univariate logistic regression significance of deter-
minants was interpreted from the Wald statistic. Multi-
ple logistic regression was done by stepwise entering of
variables to assess the combined effects of several deter-
minants. Possible interaction between determinants was
examined by adding product terms.
If ≥ 5% of valid cases were missing for any item, they
were explored for non-randomness of the main demo-
graphic variables (gender, level of education, and where
relevant Pompe status). Missing data were not analysed
in regression analyses.
Results and discussion
Response and inclusion
The response rate was 51% for consumer panel mem-
bers and 59% for patient association members (Table 1).
Since basic demographics were available for the entire
consumer panel, it could be determined that responders
were more likely to have middle and higher education
than non-responders (p = 0.01, chi squared test for
trend). The most common self-reported reasons for
non-response in the consumer panel (n = 117) were
advanced age or not having children (22%) and difficulty
of the questionnaire (18%).
Two consumer panel members reported Pompe dis-
ease (in the family). We cannot exclude that they were
also members of the patient organisation, but it is unli-
kely that they would have filled out the survey twice. In
all following analyses, people with Pompe disease (in the
family) are classified together and compared to the
remaining consumer panel members, redefined as the
neutral group (Table 1 lower panel).
After presenting background information comprehen-
sion was tested. Based on the results of the pre-test, it
was expected that most people with middle or higher
education would pass the threshold (see Methods). 74%
of the neutral group and 95% of people with Pompe (in
the family) demonstrated sufficient comprehension. The
comprehension criterion led to a shift of distribution of
Table 1 Response and inclusion
Patients’ organisation Consumer panel
Response
questionnaires mailed 100 1500
questionnaires filled in (response rate)a 59 (59%) 757 (51%)
Pompe disease (in family)
Yes 59 2b
No 0 750
item missing 0 5c
Pompe disease (in family)
(n = 61)
neutral group
(n = 750)
Sufficient knowledge score
58 95% 555 74%
a Not counting 5 members of the patients’ organisation and 117 of the consumer panel who only provided their reason for non-response
b Not verified. One of these responders was later excluded due to insufficient knowledge score.
c Excluded from analysis
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educational level in the neutral group, towards middle
and higher education (p < 0.001, chi squared test for
trend).
Characteristics of study population
Table 2 shows demographic characteristics of the neu-
tral group (n = 555) and the group with Pompe disease
(in the family) (n = 58). The neutral group was slightly
older than the Pompe group (median 58 versus 52.5, p
= 0.002, Mann Whitney U). Gender, educational level,
and ethnicity were similarly distributed in both groups.
19% of the neutral group reported having a genetic dis-
ease (in the family).
Overall acceptability of screening from public health- and
users’ perspectives
Acceptability of screening from the public health point
of view was measured in two ways: whether the govern-
ment should offer screening and acceptability of rates of
unintended outcomes. 87% of the neutral group and
88% of the Pompe group felt that neonatal screening
should be offered for Pompe disease (12 missing; 95%
CI of difference -10 to 7%). When the results of the
neutral group were standardised to demographics of the
Dutch population, a very similar proportion for support
was calculated (shown in a supplementary table) [Addi-
tional file 4].
72% of the neutral group and 74% of the Pompe
group found the expected occurrence of false positives,
60 to 100 per year, acceptable (9 missing; 95% CI of
difference -11 to12%). 80% of the neutral group and
86% of the Pompe group found it acceptable that 3 to 5
cases of (probable) late-onset Pompe would be detected
annually (14 missing; 95% CI of difference -5 to 14).
The user’s perspective on neonatal screening is pri-
marily relevant for the neutral group, since people with
Pompe disease (in the family) would have access to
other, clinical genetic services before a pregnancy. 87%
of the neutral group said they would probably make use
of an offer of neonatal screening (18 missing; 95% CI 83
to 89%). The standardized proportion for the Dutch
population was very similar, though with a broader con-
fidence interval (shown in a supplementary table) [Addi-
tional file 4]. For the sake of completeness it is reported
that of respondents with Pompe disease (in the family),
88% (2 missing; 95% CI 76 to 94%) said they would use
hypothetically use neonatal screening for their disease.
Next, demographic determinants were explored for
the two main outcome measures of support for screen-
ing. For the question whether screening should be
offered by the government, univariate analysis showed
that educational level was a significant predictor for opi-
nion (Table 3A; p < 0.001). The most highly educated
Table 2 Characteristics of study populationa
Pompe (in
family)
n = 58
Neutral
group
n = 555
p
median age (range)b, c 52.5 (31-74) 58 (21-91) 0.002
gender: female 67% 62% 0.401
genetic disease in
familyd
NA 19% NA
educational levele 0.694
low 21% 18%
middle 45% 50%
high 35% 33%
ethnicityf, g 0.565
Dutch 97% 93%
Other Western country 3% 7%
Non-Western country 0% 1%
aPearson chi square except where otherwise indicated
b1 missing
cMann-Whitney U
d missing; NA = not analyzed
e16 missing
f 2 missing
g Fisher’s exact
Table 3 Approval of offer of screening by government
OR 95% CI p
A. univariate
educationa < 0.001
low 1
middle 0.64 0.25-1.60
high 0.22 0.09-0.53
genderb 0.689
male 1
female 0.90 0.55-1.49
Pompe in familyc 0.648
no 1
yes 1.06 0.46-2.43
B. multivariated
education < 0.001
low and middle 1
high 0.29 0.18-0.49
gender 0.290
male 1
female 0.75 0.45-1.27
Pompe in family 0.777
no 1
yes 1.13 0.48-2.64
a28 missing
b12 missing
c12 missing
d28 missing; odds ratios after adjustment for educational level, gender and
Pompe status
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group was less likely to favor the offer of screening than
the least educated group (OR 0.22, 95% CI 0.09 to 0.53).
Multivariate analysis was done to adjust for possible
confounding. To limit the number of interaction terms
which would have to be tested, lower and middle educa-
tional level were hereby combined in one category. Mul-
tivariate analysis showed similar odds ratios as
univariate analysis (Table 3B, OR 0.29, 95% CI 0.18 to
0.49, p < 0.001), confirming that people with a high
level of education were less likely to approve a govern-
ment offer of screening than people with a lower and
middle level of education. Having Pompe disease (in the
family) or gender did not explain approval for a govern-
ment offer of screening.
As stated earlier, the hypothetical use of screening was
relevant only in the neutral group. Univariate analysis
showed that use of screening was predicted by educa-
tional level (Table 4A; p = 0.001). The most highly edu-
cated group was less likely to use screening (OR 0.31,
95% CI 0.13 to 0.73) than the least educated group.
There was an indication that women were less likely to
use screening than men (OR 0.61, 95% CI 0.36 to 1.05).
For multivariate analysis, categories of educational level
were combined as described above. Multivariate analysis
confirmed that people with a high level of education
were less likely to use screening than people with a
lower and middle level of education (Table 4B; OR 0.36,
95% CI 0.21 to 0.61, p < 0.001) and suggested that
women might be less likely to use screening than men
(OR 0.54, 95% CI 0.31 to 0.94, p = 0.029).
Valuation of benefits and harms of unintended screening
outcomes
False positives and detection of a predisposition for late-
onset disease are unintended outcomes of neonatal
screening. Benefits and harms of these outcomes, in the
context of neonatal screening for Pompe disease, were
addressed from the parents’ views on the childs’ per-
spective, including a temporal dimension, and the
parent.
Both the neutral group and (parents of) Pompe
patients saw benefit for children, both from a short-
term and a lifetime perspective, regardless of whether
the outcome of screening was a false positive test or
early detection of (probable) late-onset disease (Table 5).
Notably, respondents with Pompe disease (in the family)
saw more benefit in early detection of late-onset disease
than did the neutral group, when considering a child’s
lifetime perspective (p = 0.017). While the neutral group
felt that a child diagnosed early with (probable) late-
onset Pompe disease would suffer some harm due to
screening, responders with Pompe (in the family)
expected significantly less harm for such a child (p =
0.011).
Both groups of respondents felt that parents con-
fronted with a false positive screening test would suffer
a moderate amount of harm (Table 5). The neutral
group valued early detection of (probable) late-onset
Pompe as more than moderately harmful for parents,
while responders with Pompe (in the family) expected
significantly less harm for such parents (p = 0.029).
Moral reasoning
Regarding autonomy of the child, the responder groups
showed similar acceptance of the fact that the child
would not make its own choice to be screened for a late
onset disease: 89% did not mind in the neutral group
and 90% in the Pompe group (9 missing, 95% CI of dif-
ference -7 to 10%). Overall, respondents found reasons
for screening more important than reasons against
screening (Figure 1). The group with Pompe (in the
family) attached less importance to the objection that
screening adds too little to children’s quality of life than
did the neutral group (p = 0.003, chi squared test for
trend).
For the neutral group the questionnaire tried to force
a choice for the decisive reason why one would probably
(not) use screening (Figure 2). Among probable users of
screening the most commonly reported, decisive reasons
to use screening were chance for a better quality of life
for the child and chance of health gain for the child
(Figure 2, top). Analysis of missing values (53 of 465
potential informants, 11%) showed that the lower the
educational level, the likelier it was that the respondent
did not report a decisive reason to use screening (p =
Table 4 Probable use of screening by the general public
OR 95% CI p
A. univariate
educationa 0.001
low 1
middle 0.73 0.31-1.75
high 0.31 0.13-0.73
genderb 0.075
male 1
female 0.61 0.36-1.05
B. multivariatec
education <0.001
low and middle 1
high 0.36 0.21-0.61
gender 0.029
male 1
female 0.54 0.31-0.94
a34 missing
b18 missing
c34 missing; odds ratios after adjustment for educational level and gender
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0.006, chi square test for trend). Among probable non-
users of screening, the most commonly reported reason
was that screening adds insufficient quality of life for
children, followed closely by other reasons (Figure 2,
bottom). Analysis of missing values (7 of 72 potential
informants, 10%) did not reveal any patterns.
Some respondents formulated their own decisive rea-
son for and/or against using screening (Figure 2, ‘other
reason’). Some (not shown) were very similar to the ten
reasons formulated in the survey. An original reason in
favor of screening would be relief if the screening were
negative (1×). Original reasons against screening were
the absence of Pompe disease in the family (6×), fatal-
ism/reluctance to treat (3×) and low disease frequency
(1×). The first category suggests that despite a ‘sufficient’
knowledge score, some respondents had not grasped the
introductory information on risk of recessive
inheritance.
Opponents of screening: exploration of motivation
It was expected that people who opposed a government
offer of screening would at least see some merit in early
detection of classic infantile disease, when considering
the individual child’s interest. This hypothesis was
explored through post-hoc analysis of selected responses
to the vignette on a child with classic infantile disease.
Among the 76 opponents of a government offer of
screening, 64 did mention a benefit in the case of classic
infantile disease, while 10 wrote ‘none’ or formulated a
harm in the space reserved for benefits (2 missing).
Discussion
The impetus for this study was that several jurisdictions
are considering the expansion of neonatal screening to
include treatable lysosomal storage disorders. Sometimes
patient advocates have promoted the expansion of neo-
natal screening for particular conditions, while evidence-
based reviews by professional experts have been more
hesitant [47]. Pompe disease is of special interest
because it exemplifies disorders where screening will
flag a population of diverse phenotypes. The opinion of
citizens is generally unknown. To our knowledge this is
the first quantitative study which measured the general
public’s opinion about neonatal screening for a specific
disorder and directly compared it to the opinion of (par-
ents of) patients with that particular disorder.
This study found evidence for rather high support for
neonatal screening for Pompe disease in the general
public, as measured among consumer panel members
who had been effectively informed prior to completing a
questionnaire. Their support was consistent, whether
questions were framed from the public health perspec-
tive (should Pompe disease be added to the neonatal
screening program?) or the personal perspective (would
you probably use the screening?), and it was confirmed
after standardization for demographics of the Dutch
population. The expected annual numbers of false posi-
tives and (probable) late-onset cases were acceptable to
most respondents in the consumer panel. Furthermore,
balancing benefits and harms within these two unsought
screening outcomes came out on the side of benefit for
the child, both in the short- and long term. Moderate
harm was expected for parents.
Public opinion as measured in this study can be com-
pared to policies formulated by experts. By far the most
common decisive reasons to use screening in this study
were the chance for a better quality of life of the child
and the chance for health gain. These preferences fit
fairly well with the criteria for neonatal screening as for-
mulated by expert advisory boards. For example, the
Health Council of the Netherlands formulated the main
goal of neonatal screening as prevention of health
damage, while it also recognized other advantages
though according them lesser weight, e.g. faster
Table 5 Valuation of benefits and harms
Child’s perspective Parents’ perspective
Pompea neutral pb Pompe neutral p
false positive scenario
effect on child 1st yearc 3.47 3.29 0.205 harm to parents 2.05 1.96 0.371
effect on child lifetimec 3.60 3.50 0.502
late-onset scenario
effect on child 1st yearc 3.57 3.44 0.444 harm to parents 1.93 1.73 0.029
effect on child lifetime 3.93 3.47 0.017
harm to childd 2.41 2.18 0.011
a mean scores; measures of effect scaled 1-5, measures of harm scaled 1-3, with harm at the low end and benefit at the high end of each scale. Items in this
table had between 4 and 9 missing values
b chi square test for trend
c exact chi square test for trend
d ’(e.g. discrimination)’
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diagnosis and better care [48]. In the U.S.A. the Secre-
tary’s Advisory Committee on Heritable Disorders in
Newborns and Children uses a very similar prioritization
[49].
Most informants in this study were not concerned
about lack of autonomy of a child being screened for
late onset disease. This may be due, at least in part, to
the fact that so-called late-onset Pompe disease may
manifest in childhood. Among the portion of the general
public who would not use screening, the most common
decisive reason was concern that a test outcome of ‘pos-
sibly late-onset Pompe disease’ is too burdensome for a
Figure 1 Valuation of various moral reasons to screen (or not to screen): comparison of neutral and Pompe groups. Top: importance of
reasons to screen1. Bottom: Importance of reasons not to screen2. Open squares = Pompe group, solid squares = neutral group. 1Mean scores of
3-point scale, starting at 1 ‘unimportant’. Items in top figure had between 10 and 13 missing values. P values of exact chi square test for trend:
clockwise, starting at chance for better quality of life child: 0.409, 0.304, 0.665, 0.624, 0.317. 2Items in bottom figure had 18 to 27 missing values.
P values of (*exact) chi square test for trend: clockwise, starting at test result too burdensome for child: 0.290, 0.228, 0.410, 0.003, 0.661*.
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growing child, which relates to the ethical principle of
avoiding harm. It is difficult to relate this finding to cur-
rent policy, because screening children for broad pheno-
type conditions is not addressed in guidelines such as
the ESHG guideline for genetic testing of children [50]
or guidelines for genetic screening for chronic condi-
tions [51]. Notably, testing of asymptomatic children is
discouraged unless it has consequences for preventive,
medical actions during childhood.
This study had complex findings on whether (parents
of) patients with Pompe disease differ from the general
public in their support for neonatal screening for their
disease. On the one hand (parents of) patients did not
exceed the position of the general public when consider-
ing neonatal screening from a public health- or popula-
tion perspective (approval of a government offer of
screening, acceptability of rates of false positives and
late-onset detection). On the other hand, (parents of)
Pompe patients were more supportive of early detection
of late-onset disease than the general public; they
expected more benefit for such children on a lifetime
scale and less harm for their parents. Moral reasoning
around screening was similar for the general public and
(parents of) patients, with one exception. (Parents of)
patients were less concerned than the general public
that screening might not improve children’s quality of
life sufficiently to justify screening. Taken together,
these results show that (parents of) patients are as sensi-
tive as the general public to most concerns around neo-
natal screening for Pompe disease, but (parents of)
patients expect more benefit from early detection of
late-onset disease than the general public.
Univariate regression analysis showed that educational
level explained approval of screening. A post-hoc multi-
variate analysis, in which some categories were com-
bined, showed that independent of Pompe status, people
with high educational level were more likely to be
reserved about screening than people with middle or
lower education. Further studies should try to confirm
this finding, which may be related to the phenomenon
that lower educational level is associated with approval
for expanding neonatal screening to include untreatable
diseases [35]. Regression analyses also suggested that
women might be more likely to be reluctant to use
screening than men, but the broad confidence interval
does not support a strong effect of gender.
This study has several limitations. First, standardization
was only done for age and gender or educational level,
while other demographic variables may also explain atti-
tude towards neonatal screening for Pompe disease. For
the group familiar with Pompe disease, this study did not
differentiate between parents and patients, who might well
have distinctive perspectives. Next, selection bias may
have occurred against the least educated stratum of the
targeted population, i.e. people with prevocational second-
ary education who were classified within lower education.
The questionnaire was not pre-tested on readers from this
stratum. In the consumer panel, lower education was a
risk factor for non-response, for failing the comprehension
quiz and for skipping the question on decisive reason to
use screening. It is not clear whether lower education also
played a role in non-response for the Pompe group. Since
the comprehension cut-off used for inclusion excluded a
fair proportion (26%) of consumer panel members from
analysis, it is noted that over 90% of the excluded group
supported an offer of screening and would probably use
screening (5 to 8% missing). This suggests that more leni-
ent inclusion criteria would not have changed the study’s
main conclusions.
Although comprehension was an inclusion criterion,
there was some evidence of information bias. First, the
fact that some respondents from the general public
would decline screening because Pompe does not occur
in their family shows that the introductory information
did not always succeed in conveying the risk of recessive
inheritance. Misconceptions in this area are common,
Figure 2 Decisive moral reason to use (or not to use)
screening by neutral group. Top: probable users of screening1.
Bottom: probable non-users of screening2. See text for missing
value analyses. 1Moral reasons given by 412 of 465 probable users.
2Moral reasons given by 65 of 72 probable non-users.
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and the written information provided in this study was
not followed up by face-to-face discussion or counsel-
ling. Second, readers’ comments in the pre-test phase
suggested confusion with the question “What do you
think is the net effect of the screening on this child in
its first year of life?” on the late-onset scenario. Respon-
ders were unsure which specific benefits and harms they
should be weighing, or they found it unacceptable to
explicitly offset harms and benefits. Despite possibly
weak validity, the question was retained because it cre-
ated a temporal contrast with the following question,
which addressed the life-time perspective.
Conclusions
The rather high public support measured in the Nether-
lands for neonatal screening for Pompe disease may be
shared by citizens of other countries with a similar level
of health care. Yet in other countries too some people,
including a portion of the patient community, may have
reservations about adding this condition to a state-run
public health program. Results of this study suggest that
it would be challenging to effectively inform less-well
educated parents about the opportunities and risks of
neonatal screening for a broad-phenotype condition like
Pompe disease. This is especially important for jurisdic-
tions like the Netherlands, which aim for informed con-
sent from parents prior to neonatal screening. Yet
regardless of whether screening is mandatory, citizens’
views are important for policy-makers and legislators
who are judging the benefit-to-risk balance of screening
for a new condition. Therefore additional studies should
be undertaken to confirm which determinants explain
the range of public opinion on neonatal screening for a
broad-phenotype condition like Pompe disease. Finally,
the hesitation expressed by some respondents for
screening for a broad phenotype at birth may be con-
strued as encouragement for exploring alternative ways
to shorten the diagnostic delay of Pompe disease.
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